Skip to main content
LIPID MAPS®
menu
Databases
LMSD
LMPD
COMP_DB
LMISSD
Ion Mobility
Partial Spectra DB
Standards Spectra DB
Oxidized Phospholipid DB
Shorthand DB
Pathways
Reactions Explorer
LIPID MAPS® Pathways
SphinGOMAP©
Cayman Pathway Maps
Tools
Lipidomics
Tool Guide
MS Analysis
Structure
Drawing
Statistical
Analysis
Nomenclature
Tools
Lipid Analysis
Software
Education
Webinars
Podcasts
Tutorials
Resources
Classification
Nomenclature
Structure
Methods and
Protocols
Training
School
Community
Lipid of the
Month
Lipid Matters
Blog
Highlights
LipidWeb
Newsletters
External
Resources
Events Calendar
About
About Us
About Our
Partners
About Our
Sponsors
Sponsor Us
Contact Us
Archive
Downloads
Downloads Hub (All)
Experimental Data
REST
SPARQL
LMSD
LMPD
COMP_DB
PARTIAL_DB
Standards Spectra DB
login
Login
Microarray analysis of bone marrow-derived macrophage cells treated with Kdo
2
-lipid A (KLA) and ATP
Search by fold change ratio
|
Search by KEGG pathway
|
Search by LIPID MAPS lipid pathway
Kdo
2
-Lipid A / ATP gene array data - treatment:control ratios
KEGG pathway: Long-term depression (mmu04730)
Legend:
: View data/graphs for replicates
Gene symbol  
Time course plot
Accession
Description
Treatment
15min
30min
1hr
2hr
4hr
8hr
20hr
AK082687
KLA
ATP
ATP+KLA
AK082687
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230086D05 product:unclassifiable, full insert sequence [AK082687]
KLA
1.00
.95
1.04
.95
1.01
1.01
1.14
ATP
1.00
.96
1.03
1.05
.92
1.02
.89
KLA/ATP
1.01
1.09
1.04
1.03
1.05
1.01
1.02
Araf
KLA
ATP
ATP+KLA
NM_009703
v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703]
KLA
.87
.80
.89
.93
1.10
1.19
1.16
ATP
1.09
1.11
1.19
1.18
.78
.53
1.18
KLA/ATP
1.00
.95
.99
.93
.63
.55
1.27
BE980448
KLA
ATP
ATP+KLA
BE980448
gb|UI-M-BG2-bci-g-09-0-UI.s1 NIH_BMAP_MSC_S1 Mus musculus cDNA clone UI-M-BG2-bci-g-09-0-UI 3. [BE980448]
KLA
.97
.93
.89
.98
.96
.95
.93
ATP
1.02
1.03
.99
.97
.99
.97
1.01
KLA/ATP
.91
.88
.84
.89
.93
.96
.91
Braf
KLA
ATP
ATP+KLA
NM_139294
Braf transforming gene (Braf), mRNA [NM_139294]
KLA
1.52
1.57
1.55
1.33
1.83
1.52
1.60
ATP
1.08
1.17
1.02
1.37
.95
1.15
.95
KLA/ATP
1.64
1.69
1.39
1.51
1.04
1.31
1.26
Cacna1a
KLA
ATP
ATP+KLA
NM_007578
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578]
KLA
.71
.66
.61
.63
.60
.71
.72
ATP
1.07
1.04
.89
1.08
.71
.56
.75
KLA/ATP
.71
.72
.85
.69
.64
.63
.68
Crhr1
KLA
ATP
ATP+KLA
NM_007762
corticotropin releasing hormone receptor 1 (Crhr1), mRNA [NM_007762]
KLA
1.00
1.05
1.06
1.05
1.06
1.06
1.05
ATP
1.04
.97
1.03
1.06
1.09
1.07
1.03
KLA/ATP
1.08
1.10
1.05
1.11
1.10
1.05
1.13
Gna11
KLA
ATP
ATP+KLA
NM_010301
guanine nucleotide binding protein, alpha 11 (Gna11), mRNA [NM_010301]
KLA
.62
.65
.69
.79
.94
1.00
.96
ATP
1.00
.94
.63
.53
.79
1.13
1.22
KLA/ATP
.64
.60
.56
.55
.81
1.16
1.18
Gna12
KLA
ATP
ATP+KLA
M63659
gb|Mouse G-alpha-12 protein mRNA, complete cds [M63659]
KLA
.48
.48
.49
.40
.44
.59
.60
ATP
1.08
1.15
1.00
1.39
1.02
.65
.73
KLA/ATP
.52
.50
.51
.52
.56
.66
.52
Gna13
KLA
ATP
ATP+KLA
NM_010303
guanine nucleotide binding protein, alpha 13 (Gna13), mRNA [NM_010303]
KLA
1.96
2.10
2.12
1.85
2.36
2.02
1.54
ATP
1.04
1.13
1.19
3.56
6.50
2.32
1.44
KLA/ATP
2.17
2.07
1.67
3.72
6.89
3.91
2.27
Gnai1
KLA
ATP
ATP+KLA
NM_010305
guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305]
KLA
.95
1.01
1.01
1.00
1.09
1.10
1.08
ATP
1.06
1.06
.99
1.15
1.02
.94
.99
KLA/ATP
1.02
1.04
.99
1.16
1.01
1.02
1.13
Gnai2
KLA
ATP
ATP+KLA
NM_008138
guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138]
KLA
.74
.79
.82
.74
.91
.97
1.10
ATP
1.07
1.16
.78
1.12
.78
.48
.82
KLA/ATP
.91
.81
.53
.80
.60
.68
.87
Gnai3
KLA
ATP
ATP+KLA
NM_010306
guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306]
KLA
1.23
1.24
1.14
1.06
.99
1.15
1.09
ATP
.96
.93
.86
.64
1.34
2.02
1.35
KLA/ATP
1.20
1.24
.97
.76
1.21
1.62
1.17
Gnao1
KLA
ATP
ATP+KLA
NM_001113384
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384]
KLA
.95
.98
1.03
1.00
1.02
1.02
.99
ATP
.95
1.02
1.01
1.08
.99
.97
.95
KLA/ATP
1.05
1.04
1.10
.99
1.01
.98
1.03
Gnao1
KLA
ATP
ATP+KLA
NM_010308
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308]
KLA
.98
.96
1.00
.97
.96
.97
1.01
ATP
1.12
.99
1.05
.87
.97
1.02
1.01
KLA/ATP
.93
1.00
.99
1.01
1.05
1.07
.98
Gnaq
KLA
ATP
ATP+KLA
NM_008139
guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139]
KLA
.82
.82
.69
.64
.60
.55
.55
ATP
1.06
1.02
.87
.67
.50
.66
.57
KLA/ATP
.82
.79
.66
.55
.41
.33
.48
Gnas
KLA
ATP
ATP+KLA
AF107847
neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847]
KLA
1.04
.94
1.00
1.05
1.04
.98
1.00
ATP
.98
.97
.96
1.00
.99
.98
1.02
KLA/ATP
1.04
1.02
.96
.95
1.01
.96
1.01
Gnas
KLA
ATP
ATP+KLA
AK017423
10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423]
KLA
.85
1.08
.97
.92
1.05
1.03
1.08
ATP
.99
1.30
2.11
1.73
1.23
1.01
1.02
KLA/ATP
.96
1.06
1.58
1.34
1.29
1.05
.91
Gnas
KLA
ATP
ATP+KLA
NM_001077510
GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510]
KLA
.99
1.03
.97
.91
1.03
.95
.97
ATP
1.04
1.19
1.15
1.61
1.24
.91
1.00
KLA/ATP
1.06
.97
1.01
1.46
1.04
.85
1.01
Gnas
KLA
ATP
ATP+KLA
S49980
gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980]
KLA
.91
.88
1.03
.87
.90
.84
1.01
ATP
1.16
1.22
1.02
1.55
1.16
.80
.99
KLA/ATP
1.01
1.13
.86
1.12
.97
.85
1.08
Gnaz
KLA
ATP
ATP+KLA
NM_010311
guanine nucleotide binding protein, alpha z subunit (Gnaz), mRNA [NM_010311]
KLA
1.04
1.02
1.02
1.04
.95
.98
1.03
ATP
1.00
1.03
.98
1.03
1.08
1.03
.96
KLA/ATP
1.08
1.03
1.02
1.04
1.01
1.00
1.02
Gria1
KLA
ATP
ATP+KLA
NM_008165
glutamate receptor, ionotropic, AMPA1 (alpha 1) (Gria1), transcript variant 2, mRNA [NM_008165]
KLA
.97
1.02
1.02
1.01
1.03
1.02
1.11
ATP
1.03
.97
1.05
1.03
1.01
1.01
1.01
KLA/ATP
1.02
.99
1.01
1.06
1.15
1.06
1.05
Gria2
KLA
ATP
ATP+KLA
BC048248
glutamate receptor, ionotropic, AMPA2 (alpha 2), mRNA (cDNA clone MGC:54603 IMAGE:6494013), complete cds. [BC048248]
KLA
1.00
1.01
1.05
1.00
1.03
.97
1.06
ATP
.98
1.00
1.00
.96
1.03
1.05
1.04
KLA/ATP
.98
1.08
.99
1.04
1.06
1.02
1.05
Gria2
KLA
ATP
ATP+KLA
NM_013540
glutamate receptor, ionotropic, AMPA2 (alpha 2) (Gria2), transcript variant 2, mRNA [NM_013540]
KLA
1.02
1.02
.98
1.01
.98
1.02
1.01
ATP
.95
1.01
.95
.99
1.09
1.02
1.09
KLA/ATP
1.06
.92
.96
.99
1.00
1.03
1.00
Gria3
KLA
ATP
ATP+KLA
AK161163
0 day neonate head cDNA, RIKEN full-length enriched library, clone:4831401I16 product:glutamate receptor, ionotropic, AMPA3 (alpha 3), full insert sequence. [AK161163]
KLA
1.01
.96
.97
.95
.99
.84
.81
ATP
1.05
1.04
1.07
.86
.88
.84
.65
KLA/ATP
.94
.95
1.06
.83
.79
.75
.66
Gria3
KLA
ATP
ATP+KLA
NM_016886
glutamate receptor, ionotropic, AMPA3 (alpha 3) (Gria3), mRNA [NM_016886]
KLA
1.04
.95
1.05
.98
.98
.97
.95
ATP
1.00
1.08
1.01
.97
.93
.98
.97
KLA/ATP
1.03
.93
.93
.98
.96
1.03
.89
Grid2
KLA
ATP
ATP+KLA
AK032669
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:6530411F08 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK032669]
KLA
1.00
1.02
1.01
1.01
1.01
1.01
1.00
ATP
1.01
1.01
.99
.99
1.01
1.01
1.00
KLA/ATP
1.02
1.01
1.01
1.02
.99
1.01
.99
Grid2
KLA
ATP
ATP+KLA
AK036230
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630046P05 product:glutamate receptor, ionotropic, delta 2, full insert sequence. [AK036230]
KLA
1.01
.97
1.01
.96
.96
.96
1.06
ATP
1.00
1.01
1.01
.97
1.00
.97
1.03
KLA/ATP
1.02
1.06
1.02
.92
.95
.95
.99
Grm1
KLA
ATP
ATP+KLA
NM_016976
glutamate receptor, metabotropic 1 (Grm1), transcript variant 1, mRNA [NM_016976]
KLA
1.16
1.07
1.10
1.18
1.08
1.04
1.15
ATP
1.06
1.05
1.02
.99
1.00
1.09
1.02
KLA/ATP
1.04
1.12
1.06
1.11
1.10
1.32
1.35
Gsbs
KLA
ATP
ATP+KLA
AF071562
G-substrate mRNA, complete cds. [AF071562]
KLA
1.01
.99
.99
1.00
1.05
.98
.98
ATP
1.02
1.03
1.04
1.00
.93
.93
.97
KLA/ATP
1.00
.97
.96
.88
1.00
.93
.97
Gsbs
KLA
ATP
ATP+KLA
NM_011153
G substrate (Gsbs), mRNA [NM_011153]
KLA
1.02
1.09
.96
1.01
1.04
1.03
1.00
ATP
1.01
.99
1.02
1.08
.92
1.12
1.06
KLA/ATP
1.02
.91
1.05
1.01
1.04
1.01
1.06
Gucy1a3
KLA
ATP
ATP+KLA
NM_021896
guanylate cyclase 1, soluble, alpha 3 (Gucy1a3), mRNA [NM_021896]
KLA
1.01
1.01
1.04
.99
.99
.97
.99
ATP
.99
1.01
.99
.99
.97
1.02
1.02
KLA/ATP
1.00
.96
1.00
.99
.98
1.04
.99
Gucy1b2
KLA
ATP
ATP+KLA
NM_172810
guanylate cyclase 1, soluble, beta 2 (Gucy1b2), mRNA [NM_172810]
KLA
1.02
1.03
1.03
1.09
.95
1.06
.91
ATP
1.01
1.03
1.01
1.08
.96
1.04
.90
KLA/ATP
1.04
1.03
.99
1.05
.97
.96
.84
Gucy1b3
KLA
ATP
ATP+KLA
NM_017469
guanylate cyclase 1, soluble, beta 3 (Gucy1b3), mRNA [NM_017469]
KLA
.99
.99
.99
1.01
.98
.98
1.00
ATP
.98
.98
.98
.98
.98
1.00
1.01
KLA/ATP
.96
.99
.98
1.01
.99
.99
.99
Hras1
KLA
ATP
ATP+KLA
NM_008284
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284]
KLA
.79
.82
.77
.82
.94
1.03
1.07
ATP
1.01
.95
.69
.83
.79
1.12
1.15
KLA/ATP
.84
.77
.61
.65
.82
1.00
1.05
Igf1
KLA
ATP
ATP+KLA
AK050118
adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730016P09 product:unclassifiable, full insert sequence. [AK050118]
KLA
.13
.14
.15
.16
.22
.34
.48
ATP
1.78
2.05
1.37
.72
.34
.41
.58
KLA/ATP
.24
.45
.50
.24
.20
.26
.68
Igf1
KLA
ATP
ATP+KLA
NM_010512
insulin-like growth factor 1 (Igf1), transcript variant 1, mRNA [NM_010512]
KLA
.84
.78
.76
.67
.54
.48
.59
ATP
.97
.98
1.13
1.13
1.03
.88
.89
KLA/ATP
.82
.81
.93
.86
.83
.65
.89
Igf1
KLA
ATP
ATP+KLA
NM_184052
insulin-like growth factor 1 (Igf1), transcript variant 2, mRNA [NM_184052]
KLA
.77
.82
.76
.65
.60
.52
.69
ATP
1.01
1.07
.98
1.06
1.03
.78
.94
KLA/ATP
.89
.86
.77
.80
.75
.65
.89
Igf1r
KLA
ATP
ATP+KLA
NM_010513
insulin-like growth factor I receptor (Igf1r), mRNA [NM_010513]
KLA
1.32
1.32
1.08
.91
.55
.48
.45
ATP
1.03
1.06
1.06
1.29
1.31
1.45
.47
KLA/ATP
1.30
1.37
1.11
1.00
.93
1.02
.45
Itpr1
KLA
ATP
ATP+KLA
NM_010585
inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585]
KLA
3.66
3.69
6.74
8.11
7.08
4.40
1.22
ATP
1.08
.95
1.19
.94
1.09
1.00
.68
KLA/ATP
3.48
3.58
5.86
6.03
4.01
2.31
.97
Itpr2
KLA
ATP
ATP+KLA
NM_019923
inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923]
KLA
1.41
1.38
1.43
1.42
1.30
1.07
1.01
ATP
1.00
1.00
.97
.97
1.07
1.15
1.06
KLA/ATP
1.39
1.48
1.64
1.42
1.07
.83
.95
Itpr3
KLA
ATP
ATP+KLA
NM_080553
inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553]
KLA
.55
.51
.45
.41
.34
.34
.45
ATP
1.01
.92
1.02
.57
.46
.34
1.22
KLA/ATP
.56
.48
.48
.29
.33
.27
.65
Kras
KLA
ATP
ATP+KLA
NM_021284
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284]
KLA
.53
.49
.40
.42
.49
.95
1.05
ATP
.98
1.01
1.16
1.17
1.39
1.29
1.74
KLA/ATP
.50
.47
.50
.56
1.00
1.24
1.58
LOC10004
8021
KLA
ATP
ATP+KLA
XM_001479354
ref|PREDICTED: Mus musculus similar to Guanine nucleotide-binding protein alpha-12 subunit (G alpha-12) (LOC100048021), mRNA [XM_001479354]
KLA
.29
.29
.23
.19
.25
.43
.47
ATP
1.03
1.08
.94
.88
.78
.52
.59
KLA/ATP
.32
.29
.20
.22
.31
.47
.36
Lyn
KLA
ATP
ATP+KLA
NM_010747
Yamaguchi sarcoma viral (v-yes-1) oncogene homolog (Lyn), transcript variant 2, mRNA [NM_010747]
KLA
2.48
2.80
3.76
3.81
5.30
4.57
2.46
ATP
1.06
1.18
.82
.97
.74
1.45
1.21
KLA/ATP
2.82
3.16
2.24
2.87
1.73
1.80
2.63
Map2k1
KLA
ATP
ATP+KLA
NM_008927
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927]
KLA
1.82
2.00
2.31
2.03
2.51
2.20
1.51
ATP
.99
1.14
.81
.87
.90
1.57
1.11
KLA/ATP
1.90
2.03
1.50
1.93
1.63
2.03
2.06
Map2k2
KLA
ATP
ATP+KLA
NM_023138
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138]
KLA
.96
1.01
1.09
.99
1.11
1.15
1.42
ATP
1.07
1.05
.74
.86
1.04
1.16
1.21
KLA/ATP
1.14
1.03
.68
.78
.85
1.01
1.20
Mapk1
KLA
ATP
ATP+KLA
NM_001038663
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663]
KLA
.97
1.03
.93
.86
.79
1.01
1.04
ATP
.96
1.18
1.01
1.13
.84
1.04
1.16
KLA/ATP
.99
.99
.84
.87
.63
.96
1.26
Mapk1
KLA
ATP
ATP+KLA
NM_011949
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949]
KLA
.88
.80
.80
.73
.75
.76
.65
ATP
.97
.96
1.06
.88
.90
.68
.48
KLA/ATP
.82
.81
.78
.65
.64
.64
.45
Mapk3
KLA
ATP
ATP+KLA
NM_011952
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952]
KLA
.81
.85
.88
.72
.79
.73
.90
ATP
1.13
1.30
.92
1.48
1.08
.68
1.03
KLA/ATP
1.01
1.01
.66
1.13
.77
.77
1.16
Mm.22094
6
KLA
ATP
ATP+KLA
27545180
Unknown
KLA
1.00
.93
.97
1.05
1.06
1.29
1.13
ATP
.90
.94
1.25
1.18
.85
.62
1.20
KLA/ATP
.86
.99
1.14
.99
.83
.70
1.26
Mm.27574
2
KLA
ATP
ATP+KLA
112983655
Unknown
KLA
1.35
1.16
.94
.85
.45
.33
.31
ATP
.90
.86
1.17
1.09
1.18
1.21
.38
KLA/ATP
1.12
1.22
1.19
.91
.90
.83
.33
Mm.33050
7
KLA
ATP
ATP+KLA
67906182
Unknown
KLA
.94
.98
.99
1.03
1.05
1.07
.98
ATP
.95
1.02
.97
.98
.99
1.05
1.02
KLA/ATP
1.02
1.05
1.01
1.03
.99
.98
.97
Mm.44160
1
KLA
ATP
ATP+KLA
145966786
Unknown
KLA
1.08
.94
1.01
.97
.79
.78
.71
ATP
1.09
.92
1.10
.75
.65
.92
.69
KLA/ATP
1.01
.92
1.16
.81
.69
.56
.63
Nos1
KLA
ATP
ATP+KLA
NM_008712
nitric oxide synthase 1, neuronal (Nos1), mRNA [NM_008712]
KLA
1.01
1.01
1.02
.99
1.02
1.02
1.01
ATP
1.01
1.03
1.02
1.04
1.03
1.01
1.00
KLA/ATP
1.05
1.02
1.02
1.00
1.02
1.03
1.03
Nras
KLA
ATP
ATP+KLA
NM_010937
neuroblastoma ras oncogene (Nras), mRNA [NM_010937]
KLA
1.20
1.22
1.27
1.20
1.09
.91
.84
ATP
.98
.91
.69
.61
.59
.67
.78
KLA/ATP
1.22
1.14
.97
.79
.73
.61
.72
Pla2g4a
KLA
ATP
ATP+KLA
NM_008869
phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869]
KLA
3.93
4.49
4.86
6.40
6.44
3.10
1.68
ATP
1.13
1.36
1.27
1.30
1.02
5.37
1.47
KLA/ATP
3.64
4.45
4.76
7.11
2.96
4.08
2.60
Pla2g4b
KLA
ATP
ATP+KLA
NM_145378
phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378]
KLA
1.09
1.18
.95
1.01
.97
.97
.77
ATP
1.05
1.14
1.28
.94
.88
1.18
.70
KLA/ATP
1.23
1.43
1.21
1.02
1.15
1.16
.78
Pla2g4c
KLA
ATP
ATP+KLA
AK145339
1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339]
KLA
1.09
1.21
1.33
1.17
1.26
1.30
1.05
ATP
.97
1.06
1.00
.98
.98
.98
1.05
KLA/ATP
1.19
1.16
1.18
1.13
1.04
1.02
1.06
Pla2g4c
KLA
ATP
ATP+KLA
NM_001004762
phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762]
KLA
.93
1.00
.94
.93
.94
.94
.96
ATP
.98
.96
1.13
.97
.99
.89
.96
KLA/ATP
1.01
1.01
1.07
1.01
.94
1.01
.92
Pla2g4e
KLA
ATP
ATP+KLA
AK049063
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063]
KLA
1.03
1.09
1.01
1.01
1.06
.94
1.05
ATP
1.03
1.00
1.06
1.01
.96
1.05
1.05
KLA/ATP
.98
1.00
1.01
.98
1.03
.95
1.01
Pla2g4e
KLA
ATP
ATP+KLA
NM_177845
phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845]
KLA
.97
.95
1.01
.97
1.02
1.03
1.05
ATP
.98
.99
1.00
1.10
.98
1.00
1.02
KLA/ATP
1.05
.93
.96
1.03
1.08
1.05
.99
Pla2g4f
KLA
ATP
ATP+KLA
NM_001024145
phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145]
KLA
1.08
.99
1.04
1.02
1.04
.98
1.01
ATP
.99
1.04
.99
1.03
1.12
1.01
1.25
KLA/ATP
.97
1.04
1.10
1.06
1.04
1.03
1.03
Plcb1
KLA
ATP
ATP+KLA
AK129166
mRNA for mKIAA0581 protein [AK129166]
KLA
1.02
.98
.91
.91
.92
.95
.89
ATP
1.03
1.02
1.02
1.01
.90
1.02
1.04
KLA/ATP
.98
.97
.91
.93
.92
1.01
1.16
Plcb1
KLA
ATP
ATP+KLA
NM_019677
phospholipase C, beta 1 (Plcb1), mRNA [NM_019677]
KLA
.99
.94
.95
.97
.93
.92
.91
ATP
1.00
.96
.99
.95
.99
1.03
.98
KLA/ATP
.93
.96
.94
.93
.87
1.00
1.06
Plcb2
KLA
ATP
ATP+KLA
NM_177568
phospholipase C, beta 2 (Plcb2), mRNA [NM_177568]
KLA
.70
.68
.64
.67
.65
.76
.88
ATP
.95
.94
1.04
.94
.72
.57
1.19
KLA/ATP
.69
.68
.72
.63
.65
.55
.70
Plcb3
KLA
ATP
ATP+KLA
NM_008874
phospholipase C, beta 3 (Plcb3), mRNA [NM_008874]
KLA
1.72
1.78
1.82
1.65
1.67
1.44
1.21
ATP
.97
1.04
.81
.87
.78
.88
.94
KLA/ATP
1.69
1.89
1.44
1.66
1.12
.73
.93
Plcb4
KLA
ATP
ATP+KLA
AK082509
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509]
KLA
1.06
1.03
.97
.98
1.02
1.01
.99
ATP
.99
1.07
1.09
.95
.97
.97
1.02
KLA/ATP
.98
1.00
1.03
.96
1.02
.91
.98
Plcb4
KLA
ATP
ATP+KLA
NM_013829
phospholipase C, beta 4 (Plcb4), mRNA [NM_013829]
KLA
.88
.94
.81
.82
.81
.86
1.01
ATP
1.00
1.01
.92
.93
.88
.85
.89
KLA/ATP
.97
.94
.78
.80
.78
.86
.97
Ppp2ca
KLA
ATP
ATP+KLA
NM_019411
protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform (Ppp2ca), mRNA [NM_019411]
KLA
1.17
1.13
1.18
1.20
1.54
1.45
1.34
ATP
1.09
1.20
1.07
1.33
1.56
2.04
1.43
KLA/ATP
1.14
1.17
1.15
1.49
1.59
2.37
2.02
Ppp2cb
KLA
ATP
ATP+KLA
NM_017374
protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform (Ppp2cb), mRNA [NM_017374]
KLA
1.32
1.33
1.37
1.24
1.27
1.09
1.18
ATP
.94
.93
.82
.91
1.22
2.01
1.08
KLA/ATP
1.24
1.14
.80
.97
1.13
1.54
1.18
Ppp2r1a
KLA
ATP
ATP+KLA
NM_016891
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform (Ppp2r1a), mRNA [NM_016891]
KLA
1.44
1.39
1.47
1.37
1.69
1.33
1.16
ATP
1.18
1.55
.85
1.67
1.38
.99
1.24
KLA/ATP
1.66
1.98
.97
2.33
1.41
1.65
1.38
Ppp2r1b
KLA
ATP
ATP+KLA
NM_001034085
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 1, mRNA [NM_001034085]
KLA
1.26
1.17
1.14
1.13
1.12
1.11
.99
ATP
.90
.90
.96
.98
1.59
1.71
1.16
KLA/ATP
1.23
1.16
.99
1.00
1.54
1.34
1.24
Ppp2r1b
KLA
ATP
ATP+KLA
NM_028614
protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform (Ppp2r1b), transcript variant 2, mRNA [NM_028614]
KLA
2.38
2.38
2.53
1.80
1.52
.95
1.16
ATP
1.17
1.29
1.04
1.09
1.16
1.19
1.00
KLA/ATP
2.59
2.78
1.82
2.31
1.34
1.03
.75
Prkca
KLA
ATP
ATP+KLA
NM_011101
protein kinase C, alpha (Prkca), mRNA [NM_011101]
KLA
1.00
.96
.94
.95
.95
.89
.96
ATP
1.00
1.03
.91
.94
.82
.87
1.13
KLA/ATP
1.02
.95
.91
.86
.78
.84
.94
Prkcb1
KLA
ATP
ATP+KLA
NM_008855
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855]
KLA
.92
.95
.93
.78
.77
1.08
1.83
ATP
1.03
1.12
1.09
1.23
.90
2.08
.96
KLA/ATP
.98
.99
.82
.89
.62
1.01
1.08
Prkcc
KLA
ATP
ATP+KLA
NM_011102
protein kinase C, gamma (Prkcc), mRNA [NM_011102]
KLA
1.02
1.04
1.11
1.04
.96
1.02
1.05
ATP
.98
.98
1.05
1.03
1.08
.96
.95
KLA/ATP
1.21
1.16
1.09
1.07
1.04
.98
.93
Prkg1
KLA
ATP
ATP+KLA
NM_011160
protein kinase, cGMP-dependent, type I (Prkg1), transcript variant 2, mRNA [NM_011160]
KLA
.97
.96
.97
1.08
1.11
.93
.94
ATP
1.07
.96
.94
.99
1.03
1.60
.90
KLA/ATP
.95
1.07
1.00
1.04
1.00
1.04
.91
Prkg2
KLA
ATP
ATP+KLA
NM_008926
protein kinase, cGMP-dependent, type II (Prkg2), mRNA [NM_008926]
KLA
.97
1.03
1.03
1.02
1.15
.99
.98
ATP
1.02
1.08
.98
.98
1.00
1.00
1.02
KLA/ATP
1.01
1.02
1.03
.97
1.00
.93
1.02
Raf1
KLA
ATP
ATP+KLA
AK036317
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317]
KLA
1.47
1.34
1.55
1.29
1.59
1.32
1.46
ATP
1.05
.98
.54
.63
3.32
2.07
1.01
KLA/ATP
1.57
1.33
.79
.96
2.26
1.38
1.35
Raf1
KLA
ATP
ATP+KLA
NM_029780
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780]
KLA
1.65
1.64
1.93
1.77
1.77
1.72
1.81
ATP
.95
.96
.83
.80
2.22
2.92
1.19
KLA/ATP
1.68
1.64
1.39
1.32
1.85
2.50
2.06
Ryr1
KLA
ATP
ATP+KLA
AK042482
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full
KLA
1.61
1.64
1.65
1.73
1.85
1.62
1.13
ATP
1.05
1.11
1.16
1.42
1.40
1.28
1.22
KLA/ATP
1.77
1.70
1.98
2.23
1.96
1.47
1.48
Ryr1
KLA
ATP
ATP+KLA
AK042482
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630095L05 product:RYANODINE RECEPTOR 1 (SKELETAL MUSCLE-TYPE RYANODINE RECEPTOR) (RYR1) (RYR-1) (SKELETAL MUSCLE CALCIUM RELEASE CHANNEL) homolog [Homo sapiens], full i
KLA
1.52
1.58
1.63
1.69
1.73
1.53
1.25
ATP
.99
.99
1.07
1.37
1.35
1.30
1.15
KLA/ATP
1.58
1.67
1.84
1.97
1.94
1.65
1.41
Ryr1
KLA
ATP
ATP+KLA
NM_009109
ryanodine receptor 1, skeletal muscle (Ryr1), mRNA [NM_009109]
KLA
.94
.93
.89
.91
.82
.86
.88
ATP
1.05
.98
.95
1.08
1.41
1.28
1.15
KLA/ATP
.93
.95
.92
1.02
1.62
1.96
2.06